Efficacy and safety of adjunctive midazolam with propofol-based TCI for sedated colonoscopy

Efficacy and safety of adjunctive midazolam with propofol-based TCI for sedated colonoscopy: Prospective randomized study

Status

Unknown

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230707002

Enrollment

Registered

2023-07-07

Start date

2023-07-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Propofol consumption , Hypotension while under anesthesia for colonoscopy Target-controlled infusion, Sedation for colonoscopy, Medzolam,

Interventions

The patients undergoing colonoscopy will receive Fentanyl at the dose of 0.5 mg/kg,The patients undergoing colonoscopy will be given Madzolam at the dose of 0.03 mg/kg along with Fentanyl 0.5 mg/kg

Placebo Comparator Drug,Experimental Drug

Group P,Group M

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1 Patients undergoing elective colonoscopy 2 ASA status I - III

Exclusion criteria

Exclusion criteria: 1 BMI > 35 kg/m2 2 Colostomy patients 3 Patients on epilepsy drug or benzodiazepines 4 Patients who have liver cirrhosis or end-stage kidney disease 5 Allergy to propofol, fentanyl, or benzodiazepine 6 Anticipated difficult airway

Design outcomes

Primary

Measure	Time frame
Propofol consumption during colonoscopy mg/kg/min	—

Secondary

Measure	Time frame
Ephedrine dose during colonoscopy mg	—

Countries

Thailand

Contacts

Public ContactJaramporn Pattanapichakorn

Somdej Phra Phutthaloetla Hospital, Ministry of Public Health

jpichakorn@gmail.com0818707144

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026